ASH 2018 | An update on the state-of-affairs of BiTEs in the world of AML

Marion Subklewe

At the time of this publication, there are a variety of studies exploring the optimal dose of bi-specific T-cell engager (BiTE) therapies for acute myeloid leukemia (AML). At the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Marion Subklewe, MD, of the LMU Hospital Munich, Munich, Germany, provides an overview of ongoing studies, and discusses key observations.

Share this video